Macrogenics (MGNX) Other Non-Current Assets (2012 - 2026)
Macrogenics (MGNX) posted quarterly Other Non-Current Assets of $1.4 million for Q1 2026, down 7.65% year-over-year from $1.5 million in Q1 2025, and down 0.65% quarter-over-quarter from $1.4 million in Q4 2025.
Analysis
Macrogenics (MGNX) Other Non-Current Assets (2012 - 2026) Analysis & Trends
Macrogenics (MGNX) has reported Other Non-Current Assets for 15 consecutive years, with $1.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Non-Current Assets fell 7.65% year-over-year to $1.4 million; the TTM figure through Mar 2026 stood at $1.4 million (down 7.65% YoY), while the FY2025 annual figure was $1.4 million, down 10.99% from the prior year.
- Other Non-Current Assets fell to $1.4 million in Q1 2026 per MGNX's latest filing, from $1.4 million in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $17.2 million in Q1 2022 and bottomed at $1.2 million in Q1 2024.
- Historically, Other Non-Current Assets has averaged $4.0 million across 5 years, with a median of $1.4 million in 2023.
- Annual changes were most pronounced in 2023 — Other Non-Current Assets slumped 91.99% — and 2025, when it advanced 25.74%.
- Macrogenics' Other Non-Current Assets stood at $1.4 million in 2022, then increased by 0.58% to $1.4 million in 2023, then grew by 12.27% to $1.6 million in 2024, then decreased by 10.99% to $1.4 million in 2025, then fell by 0.65% to $1.4 million in 2026.
- Business Quant data shows MGNX's Other Non-Current Assets at $1.4 million in Q1 2026, $1.4 million in Q4 2025, and $1.4 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.51 Bn | 130.66 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.24 Bn | 77.25 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 63.46 Bn | 58.28 Bn | 1.37 Bn | 124.00 Mn |
| 4 | Moderna | 57.89 Bn | 52.75 Bn | 52.00 Mn | 618.00 Mn |
| 5 | Revolution Medicines | 44.02 Bn | 44.02 Bn | - | 42.45 Mn |
| 6 | BeOne Medicines | 39.95 Bn | 34.85 Bn | 1.53 Bn | 109.58 Mn |
| 7 | Alnylam Pharmaceuticals | 35.49 Bn | 32.19 Bn | 992.69 Mn | 65.13 Mn |
| 8 | Royalty Pharma | 28.43 Bn | 27.59 Bn | - | 62.96 Mn |
| 9 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 104.44 Mn |
| 10 | Macrogenics | 279.50 Mn | 165.59 Mn | - | 195,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 195,000.00 |
| Mar 31, 2026 | 1.38 Mn |
| Dec 31, 2025 | 22.38 Mn |
| Sep 30, 2025 | 1.39 Mn |
| Jun 30, 2025 | 1.40 Mn |
| Mar 31, 2025 | 1.49 Mn |
| Dec 31, 2024 | 1.56 Mn |
| Sep 30, 2024 | 1.19 Mn |
| Jun 30, 2024 | 1.19 Mn |
| Mar 31, 2024 | 1.19 Mn |
| Dec 31, 2023 | 1.39 Mn |
| Sep 30, 2023 | 1.39 Mn |
| Jun 30, 2023 | 1.39 Mn |
| Mar 31, 2023 | 1.38 Mn |
| Dec 31, 2022 | 1.38 Mn |
| Sep 30, 2022 | 15.54 Mn |
| Jun 30, 2022 | 16.39 Mn |
| Mar 31, 2022 | 17.21 Mn |
| Dec 31, 2021 | 1.40 Mn |
| Sep 30, 2021 | 18.78 Mn |